Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does USTEKINUMAB Cause Ill-defined disorder? 1,579 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 1,579 reports of Ill-defined disorder have been filed in association with USTEKINUMAB (PYZCHIVA). This represents 1.9% of all adverse event reports for USTEKINUMAB.

1,579
Reports of Ill-defined disorder with USTEKINUMAB
1.9%
of all USTEKINUMAB reports
1,014
Deaths
1,280
Hospitalizations

How Dangerous Is Ill-defined disorder From USTEKINUMAB?

Of the 1,579 reports, 1,014 (64.2%) resulted in death, 1,280 (81.1%) required hospitalization, and 1,121 (71.0%) were considered life-threatening.

Is Ill-defined disorder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for USTEKINUMAB. However, 1,579 reports have been filed with the FAERS database.

What Other Side Effects Does USTEKINUMAB Cause?

Drug ineffective (12,471) Off label use (10,990) Product dose omission issue (9,405) Fatigue (5,457) Product use issue (5,008) Psoriasis (4,955) Pain (4,872) Rash (4,736) Crohn's disease (4,662) Arthralgia (4,608)

What Other Drugs Cause Ill-defined disorder?

ACETAMINOPHEN\OXYCODONE (9,780) ACETAMINOPHEN\HYDROCODONE (6,159) TOCILIZUMAB (4,411) RITUXIMAB (4,220) ETANERCEPT (4,202) METHOTREXATE (4,063) ABATACEPT (3,630) LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (3,600) LEFLUNOMIDE (3,570) CERTOLIZUMAB PEGOL (3,273)

Which USTEKINUMAB Alternatives Have Lower Ill-defined disorder Risk?

USTEKINUMAB vs USTEKINUMAB-STBA USTEKINUMAB vs VADADUSTAT USTEKINUMAB vs VALACYCLOVIR USTEKINUMAB vs VALBENAZINE USTEKINUMAB vs VALBENAZINE DITOSYLATE

Related Pages

USTEKINUMAB Full Profile All Ill-defined disorder Reports All Drugs Causing Ill-defined disorder USTEKINUMAB Demographics